ADS-5102 is a promising treatment option: if taken once daily at night, it achieves highest plasma drug concentrations throughout the day when symptoms are most bothersome.
Adamas announced that Gocovri extended-release capsules are now available for the treatment of dyskinesia in Parkinson's patients.
Patients with dyskinesia had a significantly higher frequency of impulse control disorders.
Gocovri is the first treatment for dyskinesia approved for patients with Parkinson's disease who are receiving levodopa therapy.
Patients in the treatment group had improved ON and OFF times and no worsening of motor function.
Dextromethorphan is thought to have an impact on all 3 therapeutic pathways for dyskinesia.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans